For the Inventor, By the Inventor

Enter assignee name

Lugano/Pazzallo, Switzerland

Helsinn Healthcare Sa

USPTO Granted Patents = 66

CIPO Patents = 4

EPO Patents = 28

Trademarks = 27

Forward Citations = 157

Loading Chart...

Loading Chart...

52 inventors (with patents filed for the assignee):

Roberta Cannella (32 out of 33 patents)

Daniele Bonadeo (23 out of 23 patents)

Claudio Pietra (19 out of 24 patents)

4. Claudio Giuliano (18 out of 19 patents)

5. Silvina Garcia Rubio (17 out of 17 patents)

6. Andrew R Miksztal (14 out of 19 patents)

7. Peter Manini (14 out of 25 patents)

8. Thomas R Malefyt (14 out of 21 patents)

9. Kathleen M Lee (14 out of 15 patents)

10. Giorgio Calderari (14 out of 14 patents)

11. Alessio Venturini (11 out of 12 patents)

12. Sergio Cantoreggi (10 out of 10 patents)

13. Fabio Trento (9 out of 11 patents)

14. Giorgia Rossi (9 out of 9 patents)

15. Alberto Macciocchi (9 out of 9 patents)

Core Competencies:

Ghrelin Agonists

NK-1 Antagonists

Fosnetupitant

Anamorelin

Injectable Formulations

Medical Treatments

Substituted Ureas

Piperazinums

Nausea Treatment

Pharmaceutical Compositions

Therapeutic Combinations

Crystalline Forms

66 patents: Sort by Forward Citations

1. 12440485 - Centrally-active ghrelin agonist and medical uses thereof (2025-10-14),

2. 12208109 - Physiologically balanced injectable formulations of fosnetupitant (2025-01-28),

3. 12071421 - Process for the synthesis of substituted chloromethyl dialkylphosphates (2024-08-27),

4. 12071406 - Crystalline forms of an NK-1 antagonist (2024-08-27),

5. 12042494 - Compositions and methods for treating centrally mediated nausea and vomiting (2024-07-23),

6. 12005056 - Centrally-active ghrelin agonist and medical uses thereof (2024-06-11),

7. 11884646 - Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, methods of preparation, and uses thereof (2024-01-30),

8. 11723902 - Medical treatments based on anamorelin (2023-08-15),

9. 11559523 - Compositions and methods for treating centrally mediated nausea and vomiting (2023-01-24),

10. 11529362 - Physiologically balanced injectable formulations of fosnetupitant (2022-12-20),

11. 11312698 - Fosnetupitant chloride hydrochloride having improved stability (2022-04-26),

12. 11299472 - Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2- trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof (2022-04-12),

13. 10961195 - Crystalline forms of an NK-1 antagonist (2021-03-30),

14. 10905737 - Methods of producing anamorelin hydrochloride having controlled chloride content (2021-02-02),

15. 10894041 - Medical treatments based on anamorelin (2021-01-19),

Helsinn Healthcare SA is a pharmaceutical company that specializes in the research and development of innovative cancer care solutions. With a focus on improving the lives of patients, Helsinn strives to provide high-quality, accessible and effective treatments. They work closely with healthcare professionals and patients to develop therapies that address unmet medical needs. Helsinn is committed to advancing cancer care through continuous innovation and collaboration with global partners.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

66 Patents

#1 in Lugano/Pazzallo

#119 in Switzerland

#10,871 in the World

Lugano/Pazzallo, Switzerland

Helsinn Healthcare Sa

Forward Citations = 157

52 inventors:

Roberta Cannella (32 out of 33 patents)

Daniele Bonadeo (23 out of 23 patents)

Claudio Pietra (19 out of 24 patents)

4. Claudio Giuliano (18 out of 19 patents)

5. Silvina Garcia Rubio (17 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…